Over the last several decades, patient recruitment for clinical trials has remained a major barrier to rapid execution of drug development programs. Sponsors are spending 20% to 60% of their time recruiting patients and about 40% of their study budgets on this task. This problem is particularly acute in oncology and with a new focus on immuno-oncology recruitment has become even more challenging.

This playbook highlights unique expertise, tools and other attributes that can help companies excel in oncology clinical trials.

Read more in our latest playbook